KPV went from a niche gut-health peptide to a regulatory headline in a few months. In July an FDA advisory committee voted 8 to 6, with one abstention, to recommend it for pharmacy compounding [1]. In late October, HHS included it in a policy that lets 503A pharmacies compound it under strict conditions [2]. Interest has followed.
KPV also has the thinnest human evidence of the six peptides in that policy. This deep dive looks at what KPV is, what the studies show, and what the HHS policy allows.
What KPV is
KPV is a tripeptide, three amino acids long: lysine, proline and valine. It is the tail end of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone made in the pituitary gland that has well-known anti-inflammatory effects [3]. Researchers became interested in KPV because it seemed to keep some of that anti-inflammatory activity in a much smaller molecule.
Alpha-MSH works mainly by binding melanocortin receptors. KPV appears to work differently. In lab studies summarized by the FDA, KPV did not displace alpha-MSH from its receptors and did not trigger the same signaling in immune cells. Experiments that blocked or removed several melanocortin receptors still showed anti-inflammatory and wound-healing effects from KPV [3]. The proposed mechanisms include blocking NF-kB, a central switch for inflammatory gene activity, and dampening the effects of inflammatory signals such as interleukin-1 beta [3].
The gut studies
Most of the KPV literature centers on inflammatory bowel disease in mice.
A 2008 study in Gastroenterology by Dalmasso and colleagues found that KPV enters intestinal lining cells and immune cells through PepT1, a transporter that normally absorbs small peptides from food. Inside the cells, KPV reduced inflammatory signaling, and oral KPV reduced the severity of two chemically induced forms of colitis in mice [4].
A second 2008 study, by Kannengiesser and colleagues in Inflammatory Bowel Diseases, tested KPV in two mouse colitis models. KPV-treated mice recovered weight faster and showed less tissue damage and fewer inflammatory cells in the colon. Mice lacking the MC1 receptor were still protected, which supports the idea that KPV works through a different route than alpha-MSH [5].
Later work focused on delivery. A 2017 study in Molecular Therapy loaded KPV into nanoparticles coated with hyaluronic acid, designed to be taken by mouth and absorbed by cells in the colon. In mice with ulcerative colitis, the formulation reduced inflammation and supported healing of the gut lining [6].
Skin and wound studies
KPV has also been studied in rodent models of wound healing, which is the use the FDA advisory committee considered [3]. The proposed products in the original nomination were creams and gels [3]. Topical KPV is popular in skincare marketing, but published human data on it are missing.
What the FDA found in humans
The FDA's July 2026 briefing document on KPV is unusually blunt. The agency said it did not identify any clinical studies in humans assessing the pharmacokinetics of KPV by any route. A search of the FDA's adverse event database through December 3, 2025 found no reports, and a literature search found no case reports of KPV use in people. FDA concluded that "potential safety risks associated with the use of KPV in humans are unknown" [3].
FDA staff also raised a manufacturing issue. KPV is sold under inconsistent names and in both free base and acetate salt forms, and the nomination itself was unclear about which form was intended [3]. The agency recommended against adding either form to the bulks list. The advisory committee voted the other way [1].
What the HHS policy allows
Under the HHS enforcement discretion policy, KPV is covered only as KPV acetate, and only for oral and topical use. Injectable KPV is outside the policy, and so is KPV free base [7].
The oral route comes with a catch. The policy expects compounders of oral peptides to keep documentation showing the formulation is adequately absorbed in humans [2]. Given that the FDA could not find any human pharmacokinetic data for KPV, it is not clear how many pharmacies will be able to meet that condition for oral products in the near term. Topical products may reach the market first.
For more on the policy as a whole, see our October coverage of the HHS decision.
How KPV compares with BPC-157
KPV often comes up alongside BPC-157, since both are pitched for gut inflammation and healing. The evidence bases differ in size. BPC-157 has decades of animal research and a handful of small human reports. KPV has a smaller set of mechanistic and mouse studies and, per the FDA, no human studies. Neither is FDA approved.
The bottom line on KPV
The mouse data for KPV in colitis are consistent and come from credible journals. The mechanism is plausible. What is missing is everything that comes after that stage: dosing studies in people, safety data and controlled trials. Anyone considering KPV under the new policy should know that the evidence is preclinical, and should involve a doctor who can monitor for problems.
You can track new studies on our KPV page.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. KPV is not FDA approved. Talk with a qualified healthcare provider before starting, stopping or changing any peptide therapy.
Sources
- Howard J. FDA advisers support easing restrictions on six peptides. Here's what those drugs are and what happens next. CNN. July 31, 2026.
- Foley & Lardner. Peptides: HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides. October 30, 2026.
- U.S. Food and Drug Administration. FDA Briefing Document: Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. KPV-related bulk drug substances.
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331.
- Xiao B, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy. 2017;25(7):1628-1640.
- U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Docket HHS-OASH-2026-0496. 91 FR 68526. October 30, 2026.